Long-term safety profile of ciprofloxacin to treat upper-respiratory tract infections The CHMP requested that applicant/ MAH provide the rationale for a 3-month treatment duration of upper respiratory tract infections and substantiate the long-term safety of the drug in such a prolonged use.